Evidence map›Paper›PMID 26298543›Full record

ReviewVirchows Archiv : an international journal of pathology2016

Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Birgitta Sander, Leticia Quintanilla-Martinez, German Ott, Luc Xerri, Isinsu Kuzu, John K C Chan, Steven H Swerdlow, Elias Campo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 77 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The pathologic diagnosis of mantle cell lymphoma.Histology and histopathology · 2021
    Review
  17. Review
  18. Review
  19. Article
  20. Haematologica · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 7 countries.

Birgitta SanderDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institutet and Karolinska University Hospital Huddinge, SE 141 86, Stockholm, Sweden. birgitta.sander@ki.se.
Leticia Quintanilla-MartinezInstitute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
German OttDepartment of Clinical Pathology, Robert-Bosch-Hospital and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Luc XerriDepartment of Bio-Pathology, Institut Paoli-Calmettes, Marseille, France.
Isinsu KuzuDepartment of Pathology, Ankara University School of Medicine, Sihhiye, Ankara, Turkey.
John K C ChanQueen Elizabeth Hospital, Hong Kong, SAR, China.
Steven H SwerdlowDivision of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Elias CampoHospital Clinic, University of Barcelona, Barcelona, Spain.
Ankara University · TRInstitut Paoli-Calmettes · FRKarolinska University Hospital · SEQueen Elizabeth Hospital · CNRobert Bosch Hospital · DEUniversitat de Barcelona · ESUniversity of Pittsburgh · USUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) is a distinctive lymphoma type generally characterized by the presence of CCND1 translocation and overexpression of cyclin D1. MCL usually presents with advanced stage and rapid clinical progression. The diagnosis is in most instances uncomplicated but cases with variant morphologies or immunophenotypes, especially cyclin D1-negative cases, may cause diagnostic difficulties. During the mantle cell lymphoma (MCL) session at the European Association of Haematopathology/Society for Hematopathology workshop 2014 held in Istanbul, Turkey, submitted cases illustrated interesting features such as unusual morphology or immunophenotypes. In several submitted cases of cyclin D1-positive MCL, CCND1 rearrangement could not be detected by t(11;14)(q13;q32) dual-color dual-fusion FISH but was suggested by CCND1 break-apart probes, and advantages and disadvantages of different FISH probes were highlighted. Three cyclin D1-negative MCL cases were submitted. These were identified by SOX11 immunohistochemistry and found to carry CCND2 translocations and/or to express high levels of cyclin D2 mRNA. Features associated with aggressive clinical course were presented including high expression of p53 protein and MYC aberrations. The need to integrate histological, immunophenotypic, genetic, and clinical data to arrive at the correct diagnosis was emphasized.

Indexed as

ImmunophenotypingIn Situ Hybridization, FluorescenceAnimalsHumansImmunohistochemistryLymphoma, B-CellLymphoma, Mantle-CellTranslocation, GeneticAggressiveFISHGenetic aberrationsImmunophenotypeIndolentMantle cell lymphomaMorphology

Identifiers

PMID26298543
OpenAlexW1873594900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.